Janssen and Arrowhead strike $3.7bn RNAi dealJanssen has struck a deal with Arrowhead Pharmaceuticals to develop an RNA interference drug to treat hepatitis B Share XJanssen and Arrowhead strike $3.7bn RNAi dealhttps://pharmaphorum.com/news/janssen-and-arrowhead-strike-3-7bn-rnai-deal/
